Info

Icagen, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of orally administered small molecule drugs that modulate ion channel targets. The Company has identified drug candidates that modulate ion channels. Its two most advanced programs are ICA-105665 for epilepsy and neuropathic pain, for which a Phase I single dose escalation study in healthy volunteers is being conducted, and Senicapoc, previously referred to as ICA-17043, for asthma, for which a Phase I multiple dose study in healthy volunteers is being conducted. Icagen is also pursuing research programs in two principal areas: pain disorders and inflammatory disorders. The Company has identified several ion channel targets that are expressed in pain pathways in both the central and peripheral nervous system.(Source: 10-K)